ACIP Recommendations: Respiratory Syncytial Virus (RSV) Vaccine Immunizations

Published in Morbidity and Mortality Weekly Report (MMWR)

The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).

CURRENT RSV vaccine immunizations

MMWR; August 15, 2024 / 73(32);696-702
Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Print version
See also:
Respiratory Syncytial Virus (RSV) Vaccine Safety
FDA self-controlled case series GBS update

MMWR; October 13, 2023 / 72(41);1115–1122
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Print version

MMWR; August 25, 2023 / 72(34);920–925
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Print version

ARCHIVED RSV immunization publications

For your convenience, these archived publications can be used for historical and research purposes.

MMWR; July 21, 2023;72(29);793–801
Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Print version